This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks Under $3

8. AEterna Zentaris (AEZS) is a drug development company focused on oncology and endocrine therapy. The company has a product pipeline with therapeutic options at various stages of development, right from drug discovery through marketed products.

Of the 12 analysts covering the stock, 67% recommend a buy and 25% suggest a hold. The stock's average 12-month price target is $4.35, which is 105.2% higher than the current price, as per a Bloomberg consensus.

For the first quarter of 2011, the company reported revenue of $7.4 million vs. $6.4 million for the same period in 2010. Cash and cash equivalents increased to $38.3 million from $32 million in the corresponding quarter of the prior year. During the quarter, the company received a net sales royalty milestone payment of $2.5 million from Cowen Healthcare Royalty Partners.

In April 2011, the company issued approximately 7.3 million common shares for aggregate gross proceeds of approximately $14.7 million. AEZS has advantages to be gained out of Perifosine -- a drug for treating multiple cancers. After the company receives license to promote the drug, as per the terms of the agreement, it would be entitled to receive $62.5 million upon achieving certain established milestone events in Japan. Besides, it is likely that AEterna Zentaris will be entitled to receive double-digit royalties on future net sales of Perifosine in the Japanese market.
3 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs